Shares Of Conatus Up 22% On FDA Fast Track Designation For NASH Cirrhosis

Yesterday, shares of Conatus Pharmaceuticals (CNAT) closed the day up 22% after the company announced that the FDA had granted the company's drug, Emricasan, FDA fast track status for NASH Cirrhosis. The company has been in back and forth talks between the FDA to achieve this fast track status. Both have agreed to start Conatus off in a trial with NASH Cirrhosis, and then begin a trial for NASH fibrosis. 

The company was able to obtain this fast track status because it submitted data from a previous trial that treated patients with portal hypertension. This trial showed remarkable efficacy after only one month of treatment with Emricasan. It seems the FDA was quite impressed and thus the FDA fast track status was given. 

Fast track is given to companies that develop drugs for unmet medical needs. Such a status gives companies the ability to get drugs approved at a quicker pace than normal. For instance, these fast track drugs get advanced review ahead of many other drugs. In addition, there is more frequent communication between the FDA and particular company. This allows the company to resolve problems or questions in a timely manner. 

Disclosure: No position in any stocks mentioned.

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
Or Sign in with
Joe Economy 8 years ago Member's comment

The FDA fast track approval for the Emricasan drug is certainly a tremendous boost to the company and a very positive belief in the importance of company's drug development. But I do fear that overall, there is a lot of risk. This is one more healthcare/biotech stock that has performed poorly over the past year but has the occasional surge when there is good news about the company. Over the past year, the stock is down 67% and year to date it is down 34%. Currently 3 analyst opinions rate this stock a strong buy while 4 rate it a buy. If you are believer in the end product, the stock could surge, but the risks are very great.